Several pharmacological inhibitors of Galectin-3 that block its carbohydrate recognition domains exist, including TD-139, which is currently being investigated in clinical studies for its therapeutic potential in fibrotic, cancer and inflammatory disorders (26, 28, 29, 40). This evidence concerns the gene LGALS3 and cancer.